|
AU2014308751B2
(en)
|
2013-08-22 |
2020-03-05 |
Acceleron Pharma, Inc. |
TGF-beta receptor type II variants and uses thereof
|
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
CA2935423C
(en)
|
2014-01-24 |
2023-11-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to pd-1 and uses thereof
|
|
AU2015210750B2
(en)
|
2014-01-31 |
2020-08-20 |
Children's Medical Center Corporation |
Antibody molecules to TIM-3 and uses thereof
|
|
EP3105246B1
(en)
|
2014-02-10 |
2021-03-31 |
Merck Patent GmbH |
Targeted tgf beta inhibition
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
WO2016040882A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of egfr inhibitors
|
|
WO2016061142A1
(en)
|
2014-10-14 |
2016-04-21 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
CN116327915A
(zh)
|
2015-04-03 |
2023-06-27 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
|
CA2986765A1
(en)
|
2015-05-29 |
2016-12-08 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
|
CN116327952A
(zh)
|
2015-08-04 |
2023-06-27 |
阿塞勒隆制药公司 |
用于治疗骨髓增生性病症的方法
|
|
WO2017020291A1
(en)
*
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
CA2996996A1
(en)
|
2015-08-31 |
2017-03-09 |
National Research Council Of Canada |
Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
|
|
ES2907486T3
(es)
*
|
2015-09-24 |
2022-04-25 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para reducir metástasis
|
|
US11583593B2
(en)
|
2016-01-14 |
2023-02-21 |
Synthis Therapeutics, Inc. |
Antibody-ALK5 inhibitor conjugates and their uses
|
|
CN109069638B
(zh)
|
2016-03-24 |
2022-03-29 |
璟尚生物制药公司 |
用于癌症治疗的三特异性抑制剂
|
|
AU2017268234A1
(en)
*
|
2016-05-17 |
2018-12-13 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
|
MX389710B
(es)
|
2016-05-27 |
2025-03-20 |
Agenus Inc |
Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
|
|
KR20190039200A
(ko)
*
|
2016-08-12 |
2019-04-10 |
메르크 파텐트 게엠베하 |
암에 대한 조합 요법
|
|
KR102617453B1
(ko)
|
2016-09-19 |
2023-12-26 |
현대모비스 주식회사 |
보조 표지판 인식 장치 및 그 방법
|
|
AU2017336546C1
(en)
|
2016-09-27 |
2025-05-29 |
Epicentrx, Inc. |
Immunomodulatory fusion proteins
|
|
KR102576042B1
(ko)
|
2016-10-11 |
2023-09-07 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
CN118634323A
(zh)
|
2016-12-07 |
2024-09-13 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
FI3551660T3
(fi)
|
2016-12-07 |
2023-12-11 |
Agenus Inc |
Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
|
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
|
EP3565599A4
(en)
*
|
2017-01-07 |
2020-07-01 |
Merck Patent GmbH |
DOSAGE PATTERNS AND DOSAGE FORMS FOR TARGETED INHIBITION OF TGF-B
|
|
CA3049652A1
(en)
*
|
2017-01-10 |
2018-07-19 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
|
GB201700567D0
(en)
|
2017-01-12 |
2017-03-01 |
Genagon Therapeutics Ab |
Therapeutic agents
|
|
AU2018207172B2
(en)
|
2017-01-13 |
2023-10-12 |
Mink Therapeutics, Inc. |
T cell receptors that bind to NY-ESO-1 and methods of use thereof
|
|
JP7231553B2
(ja)
|
2017-03-02 |
2023-03-01 |
ナショナル リサーチ カウンシル オブ カナダ |
Ｔｇｆ－ｂ－受容体外部ドメイン融合分子及びその使用
|
|
RU2765997C2
(ru)
*
|
2017-03-30 |
2022-02-07 |
Мерк Патент Гмбх |
Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
|
|
JP7297672B2
(ja)
|
2017-04-13 |
2023-06-26 |
アジェナス インコーポレイテッド |
抗ｃｄ１３７抗体およびその使用方法
|
|
JP2020517256A
(ja)
|
2017-04-19 |
2020-06-18 |
エルスター セラピューティクス， インコーポレイテッド |
多重特異性分子およびその使用
|
|
RS64576B1
(sr)
|
2017-05-01 |
2023-10-31 |
Agenus Inc |
Anti-tigit antitela i postupci njihove primene
|
|
BR112019023071A2
(pt)
*
|
2017-05-04 |
2020-06-09 |
Acceleron Pharma Inc |
proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
|
|
JP7340458B2
(ja)
*
|
2017-05-09 |
2023-09-07 |
アメリカ合衆国 |
Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ
|
|
AU2018264455B2
(en)
*
|
2017-05-12 |
2024-12-12 |
Jiangsu Hengrui Medicine Co., Ltd. |
Fusion protein containing TGF-beta receptor and medicinal uses thereof
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
BR112019025188A2
(pt)
|
2017-06-01 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
|
|
JP7387585B2
(ja)
|
2017-09-04 |
2023-11-28 |
アジェナス インコーポレイテッド |
混合系統白血病（ｍｌｌ）特異的ホスホペプチドに結合するｔ細胞受容体およびその使用方法
|
|
KR102757384B1
(ko)
|
2017-09-27 |
2025-01-20 |
에피센트알엑스, 인코포레이티드 |
면역조절 융합 단백질
|
|
CN111213059B
(zh)
*
|
2017-11-06 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
EP3720881A1
(en)
|
2017-12-08 |
2020-10-14 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
TWI823906B
(zh)
|
2018-03-09 |
2023-12-01 |
美商艾吉納斯公司 |
抗-cd73 抗體及其使用方法
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
JP2021517145A
(ja)
|
2018-03-14 |
2021-07-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
対象の腫瘍を治療するための化合物およびその使用
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
KR20210005646A
(ko)
|
2018-04-26 |
2021-01-14 |
아게누스 인코포레이티드 |
열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
|
|
WO2019213442A1
(en)
|
2018-05-03 |
2019-11-07 |
Acceleron Pharma Inc. |
MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF
|
|
WO2019213446A1
(en)
|
2018-05-03 |
2019-11-07 |
Acceleron Pharma Inc. |
NOVEL BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF
|
|
KR20210006405A
(ko)
|
2018-05-04 |
2021-01-18 |
메르크 파텐트 게엠베하 |
암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
|
|
CA3096844A1
(en)
*
|
2018-05-15 |
2019-11-21 |
Merck Patent Gmbh |
Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects
|
|
AU2019270178A1
(en)
|
2018-05-17 |
2021-01-07 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates
|
|
SG11202012426WA
(en)
*
|
2018-06-13 |
2021-01-28 |
Merck Patent Gmbh |
Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
|
|
CN111867630B
(zh)
|
2018-06-17 |
2023-10-13 |
上海健信生物医药科技有限公司 |
靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
|
|
SG11202012688UA
(en)
*
|
2018-06-22 |
2021-01-28 |
Merck Patent Gmbh |
Dosing regimens for targeted tgf-b inhibition for use in treating biliary tract cancer
|
|
WO2020006516A1
(en)
|
2018-06-29 |
2020-01-02 |
Gensun Biopharma, Inc. |
Antitumor immune checkpoint regulator antagonists
|
|
TW202019405A
(zh)
*
|
2018-07-02 |
2020-06-01 |
德商馬克專利公司 |
用於治療晚期非小細胞肺癌之標靶性TGF-β抑制之組合療法
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AU2019301070B2
(en)
*
|
2018-07-09 |
2025-09-11 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
|
AU2019325593A1
(en)
*
|
2018-08-22 |
2021-03-18 |
Merck Patent Gmbh |
Treatment of triple negative breast cancer with targeted TGF-B inhibition
|
|
CN113164777B
(zh)
|
2018-09-27 |
2024-12-13 |
马伦戈治疗公司 |
Csf1r/ccr2多特异性抗体
|
|
WO2020093024A2
(en)
|
2018-11-01 |
2020-05-07 |
Merck Patent Gmbh |
Methods of administering anti-tim-3 antibodies
|
|
JP2022505925A
(ja)
|
2018-11-01 |
2022-01-14 |
メルク パテント ゲーエムベーハー |
抗ｔｉｍ－３抗体
|
|
TWI829799B
(zh)
*
|
2018-11-09 |
2024-01-21 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種TGF-β受體融合蛋白醫藥組成物及其用途
|
|
US20210369776A1
(en)
*
|
2018-12-06 |
2021-12-02 |
Guangdong Tcrcure Biopharma Technology Co., Ltd. |
Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
EP3927745A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
US20220226491A1
(en)
|
2019-03-15 |
2022-07-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting PD-L1
|
|
EP3929215A4
(en)
*
|
2019-06-10 |
2022-06-22 |
Shandong Boan Biotechnology Co., Ltd. |
BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGF? AND ITS USE
|
|
AU2020291014B2
(en)
|
2019-06-13 |
2025-06-05 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
|
CN110218260A
(zh)
*
|
2019-06-24 |
2019-09-10 |
王跃驹 |
植物作为宿主在表达m7842中的应用
|
|
EP3990116A1
(en)
|
2019-06-28 |
2022-05-04 |
Gensun Biopharma Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
|
WO2021007428A2
(en)
*
|
2019-07-09 |
2021-01-14 |
The Johns Hopkins University |
Molecules, compositions and methods for treatment of cancer
|
|
CN112239507A
(zh)
*
|
2019-07-17 |
2021-01-19 |
鸿运华宁（杭州）生物医药有限公司 |
ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
|
|
WO2021030662A1
(en)
*
|
2019-08-15 |
2021-02-18 |
Nantbio, Inc. |
Tgf-beta trap
|
|
CN118126195A
(zh)
*
|
2019-08-30 |
2024-06-04 |
正大天晴药业集团南京顺欣制药有限公司 |
一种靶向PD-L1和TGF-β的融合蛋白及其用途
|
|
KR20220053007A
(ko)
|
2019-08-30 |
2022-04-28 |
아게누스 인코포레이티드 |
항-cd96 항체 및 이의 사용 방법
|
|
CA3148694A1
(en)
|
2019-09-03 |
2021-03-11 |
Romas Kudirka |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
EP4025255A1
(en)
|
2019-09-04 |
2022-07-13 |
Bolt Biotherapeutics, Inc. |
Immunoconjugate synthesis method
|
|
CN112442132A
(zh)
*
|
2019-09-05 |
2021-03-05 |
复旦大学 |
靶向肿瘤的重组双功能融合蛋白及其应用
|
|
CN115947846A
(zh)
|
2019-09-12 |
2023-04-11 |
普米斯生物技术(珠海)有限公司 |
一种抗pd-l1纳米抗体及其衍生物和用途
|
|
JP2022550420A
(ja)
*
|
2019-09-30 |
2022-12-01 |
ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド |
抗ｐｄ－ｌ１抗原結合タンパク質及びその応用
|
|
WO2021067242A1
(en)
|
2019-09-30 |
2021-04-08 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
|
EP4048704A4
(en)
|
2019-10-21 |
2023-11-22 |
Nanjing Leads Biolabs Co., Ltd. |
RECOMBINANT PROTEIN TARGETING PD-1 AND TGFß
|
|
KR20220088901A
(ko)
|
2019-10-25 |
2022-06-28 |
볼트 바이오테라퓨틱스 인코퍼레이티드 |
티에노아제핀 면역접합체, 및 이의 용도
|
|
CA3154413A1
(en)
*
|
2019-11-01 |
2021-05-06 |
Yan Lan |
Combined inhibition of pd-1, tgf.beta. and atm together with radiotherapy for the treatment of cancer
|
|
JP2023502585A
(ja)
*
|
2019-11-05 |
2023-01-25 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害
|
|
TW202128763A
(zh)
*
|
2019-11-12 |
2021-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
含有ＴＧＦ－β受體的融合蛋白及其醫藥用途
|
|
CN114746451A
(zh)
*
|
2019-11-27 |
2022-07-12 |
上海岸迈生物科技有限公司 |
TGFβ/PD-L1双特异性结合蛋白
|
|
WO2021115456A1
(en)
*
|
2019-12-11 |
2021-06-17 |
Wuxi Biologics (Shanghai) Co., Ltd. |
BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFβ
|
|
CN113004414B
(zh)
*
|
2019-12-20 |
2022-09-06 |
广东菲鹏制药股份有限公司 |
抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物
|
|
EP3838260A1
(en)
|
2019-12-20 |
2021-06-23 |
Ares Trading S.A. |
Igg:tgf rii fusion protein composition
|
|
US20230043290A1
(en)
*
|
2019-12-20 |
2023-02-09 |
Ares Trading S.A. |
Igg:tgfbetarii fusion protein composition
|
|
CN113121699A
(zh)
*
|
2019-12-30 |
2021-07-16 |
国典(北京)医药科技有限公司 |
Pttrap1双特异性融合蛋白及其应用
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
CN114929734A
(zh)
*
|
2020-01-09 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
新型含有4-1bbl三聚体的抗原结合分子
|
|
EP4093772A1
(en)
*
|
2020-01-21 |
2022-11-30 |
Bolt Biotherapeutics, Inc. |
Anti-pd-l1 antibodies
|
|
WO2021150701A1
(en)
|
2020-01-21 |
2021-07-29 |
Bolt Biotherapeutics, Inc. |
Anti-pd-l1 antibodies
|
|
WO2021164701A1
(en)
*
|
2020-02-18 |
2021-08-26 |
Nanjing GenScript Biotech Co., Ltd. |
Fusion proteins and uses thereof
|
|
CN115175942B
(zh)
*
|
2020-02-25 |
2025-05-30 |
上海药明生物技术有限公司 |
一种双功能融合蛋白及其用途
|
|
JP7489468B2
(ja)
*
|
2020-03-20 |
2024-05-23 |
レメゲン シーオー．，エルティーディー． |
二重特異性融合タンパク質及びその応用
|
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
CN115461362A
(zh)
*
|
2020-04-14 |
2022-12-09 |
葛兰素史密斯克莱知识产权发展有限公司 |
基于ICOS抗体和PD-L1抗体TGF-β受体融合蛋白的癌症组合疗法
|
|
KR20230028242A
(ko)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
|
|
KR20230002261A
(ko)
|
2020-04-28 |
2023-01-05 |
더 락커펠러 유니버시티 |
항-sars-cov-2 중화 항체 및 이의 사용 방법
|
|
KR20230003178A
(ko)
*
|
2020-04-29 |
2023-01-05 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
PD-1 및 TGF-β에 대한 이중 기능성 단백질
|
|
WO2021222894A1
(en)
|
2020-05-01 |
2021-11-04 |
Bolt Biotherapeutics, Inc. |
Anti-dectin-2 antibodies
|
|
CA3176626A1
(en)
|
2020-05-08 |
2021-11-11 |
David Dornan |
Elastase-substrate, peptide linker immunoconjugates, and uses thereof
|
|
JP2023532279A
(ja)
*
|
2020-06-26 |
2023-07-27 |
ソレント・セラピューティクス・インコーポレイテッド |
免疫調節性融合タンパク質を発現する腫瘍溶解性単純ヘルペスウイルス（ｈｓｖ）
|
|
IL299764A
(en)
|
2020-07-10 |
2023-03-01 |
Precigen Inc |
Fusion constructs and methods for using them
|
|
JP7766672B2
(ja)
*
|
2020-07-24 |
2025-11-10 |
▲邁▼威（上海）生物科技股▲フン▼有限公司 |
ＴＧＦ－β ＲＩＩ突然変異体及びその融合タンパク質
|
|
CN119409832B
(zh)
*
|
2020-07-28 |
2025-08-01 |
乐普生物科技股份有限公司 |
靶向PD-L1和TGF-β的双功能分子
|
|
US11028174B1
(en)
|
2020-07-28 |
2021-06-08 |
Lepu Biopharma Co., Ltd. |
Bifunctional molecules targeting PD-L1 and TGF-β
|
|
WO2022042537A1
(zh)
*
|
2020-08-24 |
2022-03-03 |
江苏恒瑞医药股份有限公司 |
TGF-β受体的融合蛋白与多靶点酪氨酸激酶抑制剂联合在制备抗肿瘤药物中的用途
|
|
CN116249718A
(zh)
|
2020-08-26 |
2023-06-09 |
马伦戈治疗公司 |
结合至钙网蛋白的多功能性分子及其用途
|
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
|
KR20230074144A
(ko)
|
2020-08-26 |
2023-05-26 |
마렝고 테라퓨틱스, 인크. |
NKp30에 결합하는 항체 분자 및 이의 용도
|
|
CN114106190B
(zh)
|
2020-08-31 |
2025-04-08 |
普米斯生物技术(珠海)有限公司 |
一种抗vegf/pd-l1双特异性抗体及其用途
|
|
WO2022042715A1
(zh)
*
|
2020-08-31 |
2022-03-03 |
杭州九源基因工程有限公司 |
靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用
|
|
WO2022057061A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
WO2022057821A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Suzhou Neologics Bioscience Co. , Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
WO2022063114A1
(zh)
*
|
2020-09-23 |
2022-03-31 |
海正生物制药有限公司 |
Tgfbr2-ecd突变体及包含其的融合蛋白与应用
|
|
WO2022063193A1
(zh)
*
|
2020-09-24 |
2022-03-31 |
上海齐鲁制药研究中心有限公司 |
同时靶向PD-L1和TGFβ的双功能分子及其医药用途
|
|
CN114349867B
(zh)
*
|
2020-10-14 |
2024-05-28 |
广东菲鹏制药股份有限公司 |
融合蛋白及其应用
|
|
WO2022090529A1
(en)
|
2020-11-02 |
2022-05-05 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
CN116801906A
(zh)
|
2020-11-02 |
2023-09-22 |
阿雷斯贸易股份有限公司 |
癌症的联合治疗
|
|
CN114573701A
(zh)
*
|
2020-12-02 |
2022-06-03 |
上海华奥泰生物药业股份有限公司 |
抗PD-L1/TGF-β双功能抗体及其用途
|
|
US20220195066A1
(en)
|
2020-12-11 |
2022-06-23 |
Bolt Biotherapeutics, Inc. |
Anti-cea immunoconjugates, and uses thereof
|
|
JP2023552790A
(ja)
|
2020-12-11 |
2023-12-19 |
ボルト バイオセラピューティクス、インコーポレーテッド |
抗ｐｄ－ｌ１イムノコンジュゲート、及びそれらの使用
|
|
JP2024501453A
(ja)
|
2020-12-11 |
2024-01-12 |
ボルト バイオセラピューティクス、インコーポレーテッド |
抗ｃｅａイムノコンジュゲート、及びそれらの使用
|
|
CN116917334B
(zh)
|
2021-02-22 |
2026-02-06 |
浙江道尔生物科技有限公司 |
一种具有抗癌活性的多结构域融合蛋白
|
|
CA3212345A1
(en)
|
2021-03-02 |
2022-09-09 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
|
CN117940168A
(zh)
|
2021-03-26 |
2024-04-26 |
博尔特生物治疗药物有限公司 |
2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
|
|
TW202304520A
(zh)
|
2021-03-26 |
2023-02-01 |
美商博特生物治療公司 |
２－胺基－４－羧醯胺－苯并氮呯免疫結合物及其用途
|
|
AU2022270880A1
(en)
|
2021-05-03 |
2023-09-28 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
|
CN114773485B
(zh)
*
|
2021-05-11 |
2024-05-17 |
江苏先声药业有限公司 |
抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
|
|
CN117999101A
(zh)
|
2021-05-25 |
2024-05-07 |
默克专利股份公司 |
靶向EGFR的Fc抗原结合片段-药物缀合物
|
|
JP2024520764A
(ja)
|
2021-06-07 |
2024-05-24 |
アレス トレーディング ソシエテ アノニム |
癌の組み合わせ処置
|
|
JP2024534263A
(ja)
*
|
2021-08-27 |
2024-09-18 |
セラノティックス カンパニー リミテッド |
Ｂ７－Ｈ３及びＴＧＦβに特異的に結合する二重特異性分子、並びにその用途
|
|
WO2023141724A1
(en)
|
2022-01-28 |
2023-08-03 |
35Pharma Inc. |
Activin receptor type iib variants and uses thereof
|
|
CN114990129B
(zh)
*
|
2022-05-11 |
2023-02-03 |
北京贝来生物科技有限公司 |
表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
|
|
TWI866210B
(zh)
|
2022-05-17 |
2024-12-11 |
大陸商蘇州創勝醫藥集團有限公司 |
雙功能蛋白質及其製劑和用途
|
|
WO2024137619A1
(en)
|
2022-12-20 |
2024-06-27 |
Bolt Biotherapeutics, Inc. |
Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
|
|
CN120981252A
(zh)
|
2023-02-14 |
2025-11-18 |
博尔特生物治疗药物有限公司 |
氮杂-苯并氮杂䓬免疫缀合物及其用途
|
|
WO2024186626A1
(en)
|
2023-03-03 |
2024-09-12 |
Bolt Biotherapeutics, Inc. |
Aza-bicyclic sting agonist immunoconjugates, and uses thereof
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024216089A1
(en)
|
2023-04-13 |
2024-10-17 |
Bolt Biotherapeutics, Inc. |
Anti-dectin-2 antibody combination therapy
|
|
AU2024372189A1
(en)
*
|
2023-10-31 |
2026-03-05 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
WO2025110822A1
(ko)
*
|
2023-11-24 |
2025-05-30 |
주식회사 메드팩토 |
피브로넥틴 엑스트라도메인 b (extradomain b of fibronectin, edb-fn) 및 전환성장인자 베타(transforming growth factor β, tgfβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도
|
|
WO2025140212A1
(en)
*
|
2023-12-26 |
2025-07-03 |
Laekna Therapeutics Shanghai Co., Ltd. |
Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof
|
|
US20260092096A1
(en)
|
2024-05-14 |
2026-04-02 |
35Pharma Inc. |
Activin receptor type iib variants and uses thereof
|
|
WO2026050213A1
(en)
|
2024-08-27 |
2026-03-05 |
Usbolt Biotherapeutics, Inc. |
Tlr agonist immunoconjugates and uses thereof
|
|
WO2026055185A1
(en)
|
2024-09-04 |
2026-03-12 |
Bolt Biotherapeutics, Inc. |
Sting agonist immunoconjugates and uses thereof
|